-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Aktis Oncology with Buy Rating, Announces Price Target of $30

Benzinga·03/09/2026 10:22:01
Listen to the news
HC Wainwright & Co. analyst Robert Burns initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Buy rating and announces Price Target of $30.